LMAT LEMAITRE VASCULAR INC

Nasdaq Surgical & Medical Instruments & Apparatus CIK: 0001158895
AI RATING
HOLD
72% Confidence

Investment Thesis

LeMaitre Vascular demonstrates exceptional operational profitability with 72.7% gross margins and 26.7% operating margins, coupled with a fortress balance sheet featuring zero debt and exceptional liquidity (14.32x current ratio). However, zero revenue growth year-over-year coupled with weak capital returns (3.9% ROE, 2.5% ROA) indicate the company is a mature cash generator rather than a growth business, failing to effectively deploy its $629.5M asset base.

Strengths

  • + Exceptional gross margin of 72.7% and operating margin of 26.7% demonstrate strong pricing power and operational efficiency in medical devices
  • + Zero debt with fortress balance sheet: 14.32x current ratio and 13.27x quick ratio provide financial safety and strategic flexibility
  • + Sustainable profitability with 23.6% net margin and positive free cash flow generation of $12.3M (18.5% FCF margin)

Risks

  • ! Critical: Zero revenue growth (0.0% YoY) indicates business stagnation with no market expansion in medical devices sector
  • ! Severely weak capital efficiency with only 3.9% ROE and 2.5% ROA despite high profitability suggests excessive asset base or goodwill from acquisitions
  • ! EPS growth of 30.6% driven entirely by non-operational sources (share buybacks, lower share count) masks underlying growth weakness

Key Metrics to Watch

Financial Metrics

Revenue
66.6M
Net Income
15.7M
EPS (Diluted)
$0.68
Free Cash Flow
12.3M
Total Assets
629.5M
Cash
26.9M

Profitability Ratios

Gross Margin 72.7%
Operating Margin 26.7%
Net Margin 23.6%
ROE 3.9%
ROA 2.5%
FCF Margin 18.5%

Balance Sheet & Liquidity

Current Ratio
14.32x
Quick Ratio
13.27x
Debt/Equity
0.00x
Debt/Assets
35.4%
Interest Coverage
13.67x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: 2026-05-07T09:40:13.525092 | Data as of: 2026-03-31 | Powered by Claude AI